HVJ liposomes and HVJ envelope vectors

Area of Science:

• Biotechnology
• Gene Therapy
• Virology

Background:

• Gene therapy requires efficient and safe delivery of therapeutic molecules into cells and tissues.
• Traditional delivery methods often face challenges like degradation and limited cellular uptake.
• Hemagglutinating Virus of Japan (HVJ), also known as Sendai virus, offers unique properties for biological applications.

Purpose of the Study:

• To describe the construction and application of fusion-mediated vectors based on inactivated HVJ.
• To present two distinct HVJ-based vector systems: HVJ liposomes and HVJ envelope vectors.
• To highlight the advantages of these vectors for delivering various therapeutic payloads.

Main Methods:

• Construction of HVJ liposomes by fusing DNA-containing liposomes with inactivated HVJ.
• Development of HVJ envelope vectors by incorporating DNA directly into inactivated HVJ particles.
• Application of these vectors for delivering plasmid DNA, proteins, peptides, oligonucleotides, and siRNA.

Main Results:

• Both HVJ liposome and HVJ envelope vectors facilitate efficient delivery of diverse molecules into cultured cells and organs.
• Fusion-mediated delivery protects therapeutic molecules from degradation, ensuring cytoplasmic access.
• Repeated in vivo administration of HVJ vectors enhances the therapeutic effects without inhibition.

Conclusions:

• HVJ-based vectors provide a versatile and effective platform for gene and molecule delivery in vitro and in vivo.
• These vectors show significant promise for various gene therapy applications, including treatment of liver cirrhosis, hearing impairment, and cancers.
• The described protocols enable the preparation and utilization of HVJ liposomes and HVJ envelope vectors for diverse therapeutic strategies.